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Abstract
Studies have shown the pharmacological relevance of phenolics like ferulic acid (FA) in promoting health. This study sought to
investigate the modulatory effects of FA on cadmium-induced brain damage in rats. Brain damage was induced in Wistar strain rats
by oral administration of cadmium (5 mg/kg body weight) for 21 days. Assays for malondialdehyde (MDA) content, acet-
ylcholinesterase (AChE), butyrylcholinesterase (BChE), monoamine oxidase (MAO), and Naþ/Kþ-ATPase activities were carried
out. The study revealed significant (P < .05) increases in the MDA content and all enzymes’ (AChE, BChE, MAO, and Naþ/Kþ-
ATPase) activity investigated following cadmium administration. However, rats administered FA (10 and 20 mg/kg body weight)
alongside cadmium significantly (P < .05) protected the brain by reversing the level of lipid peroxidation as measured by the MDA
content as well as the enzymes’ activity. This study, therefore, substantiates the neuroprotective potentials of FA especially in the
management of cadmium-induced toxicity.
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Cadmium is one of the heavy metals that contributes to serious
industrial and environmental pollution. Cadmium is nonbiode-
gradable; thus, the main source of exposure is its bioaccumula-
tion in plants grown on cadmium-polluted soil, some of which
later serve as food for humans.1 Cadmium is used in the pro-
duction of materials such as batteries, plastics, metal coatings,
and pigments, which may contaminate the soil on disposal. In
addition, occupational exposure in the course of manufacturing
these products is another source of exposure to cadmium.
Furthermore, cadmium can accumulate in several organs and
tissues and has been reported to induce damage to organs
such as testis, kidney, liver, and brain.1,2 One of the proposed
mechanisms for organ damage induced by cadmium is the
induction of free radical generation and impairment of cellular
antioxidant defense mechanisms, thus inducing oxidative
stress.3 Oxidative stress, on the other hand, can induce oxida-
tive and peroxidative damages to cellular components such
as DNA, protein, and lipid, leading to overall organ damage.
Ferulic acid (FA; Figure 1) is a natural phenolic, a derivative
of caffeic acid with wide distribution in fruits and vegetables.4
It is rapidly absorbed in the guts and does not undergo degrada-
tion by stomach acidic contents.5,6 Several findings have
reported therapeutic potentials of FA, which has been largely
linked to its antioxidant properties. Srinivasan et al7 reported
the ability of FA to prevent carbon tetrachloride–induced liver
damage in female rats by reducing plasma liver damage indices
as well as lipid and protein oxidations. Similarly, Roy et al8
reported that FA was able to restore the levels of endogenous
antioxidant enzymes (superoxide dismutase and catalase) in
pancreatic tissue of streptozotocin-induced diabetic rats.
One of the most susceptible organs to cadmium toxicity is
the brain. This is because cadmium can cross the blood-brain
barrier and promote oxidative damages1 as a result of the high
oxygen demand, high content of polyunsaturated fatty acids,
and weak endogenous antioxidant defense system of the brain.9
These ultimately lead to oxidative stress in the brain and thus
induce several neurotoxic effects that have been reported to
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Figure 1. The chemical structure of ferulic acid.
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produce symptoms such as headache, impairment in learning
and memory, and impaired peripheral nerve functions.1
Monoamine oxidase (MAO), acetylcholinesterase (AChE),
butyrylcholinesterase (BChE), and Naþ/Kþ-ATPase are unique
enzymes identified as therapeutic targets in neurodegenerative
conditions. MAO is involved in the oxidation of amine neuro-
transmitters and excessive elevation in its activity may favor
progression of depression and other neurodegenerative condi-
tions such as Alzheimer’s disease.10 Decreased brain choliner-
gic neurotransmission can lead to impairment in memory and
cognitive functions.10 AChE and BChE are enzymes of the
cholinergic system that hydrolyze acetylcholine and their mod-
ulation has been identified as possible therapeutic strategies in
the management of neurodegeneration.10 Naþ/Kþ-ATPase is
an enzyme predominant at neuronal cell membranes and func-
tions to maintain membrane potential essential for neuronal
excitability by moving (Na and K) ions across neuronal plasma
membrane.11 Consequently, impairment in the activity of Naþ/
Kþ-ATPase has been linked to neuronal damage and neurode-
generative processes in the brain.11,12
In addition, cadmium has been reported to produce diverse
modulatory effects on the cholinergic and monoaminergic neu-
ronal systems.13 On the other hand, FA has been linked to
potential neuroprotective properties partly due to their antiox-
idant effects; in an in vitro experiment, Trombino et al14
reported the ability of FA to reverse lipid peroxidation induced
in reconstituted rat brain microsome by peroxy radicals.
Therefore, in this study, we aimed to investigate the neuro-
modulatory properties of FA in cadmium-induced brain dam-
aged rats. FA (10 and 20 mg/kg body weight [bw]) were
administered over the course of 21 days, and its protective abil-
ity was investigated by assessing the level of lipid peroxidation
and its effect on Naþ/Kþ-ATPase cholinergic and monoami-
nergic enzyme activities in the rat brain tissue homogenate.
Materials and Methods
Chemical and Reagents
Chemicals such as ferulic acid, acetylthiocholine iodide, butyrylthio-
choline iodide, semicarbazide, benzylamine, adenosine triphosphate
(ATP), ouabain, ammonium molybdate, thiobarbituric acid (TBA),
dinitrophenylhydrazine (DNPH), sodium acetate, sodium dodecyl sul-
fate, phosphorus red, ascorbic acid, magnesium chloride, phosphate
buffer of different molarity, adenosine monophosphate (AMP), sodium
hydroxide, benzene, and 5,50-dithio-bis(2-nitrobenzoic acid) were pur-
chased from Sigma-Aldrich, ChemieGmH (Steinheim, Germany).
Acetic acid was procured from BDH Chemical Ltd (Poole, England).
Cadmium was sourced as cadmium chloride. Except otherwise stated,
all other chemicals and reagents were of analytical grade while water
was glass distilled. A JENWAY UV-visible spectrophotometer (Model
6305; Jenway, Barlo WORLD SCIENTIFIC, Dunmow, UK) was used
to measure absorbance throughout the experiment.
Experimental Design
Animals. Male Wistar strain rats, weighing between 150 and 160 g,
were purchased from the Central Animal House, University of Ibadan,
Ibadan, Oyo State, Nigeria. They were acclimatized for 1 week in a
stainless steel cage under controlled conditions of a 12-hour light/dark
cycle, 50% humidity, and 28C temperature. The rats were allowed
access to food and water ad libitum. All animals were used in accor-
dance with the guidelines of the Ethical Committee on Care and Use of
Experimental Animals of The Federal University of Technology,
Akure, Ondo State, Nigeria.
Treatment Groups. The animals were divided into 7 groups of 5 ani-
mals each, and all samples (cadmium, FA, and prostigmine) were
administered orally via intubation for 21 days:
Group 1: Normal rats, administered normal saline (Basal group).
Group 2: Rats administered 5 mg/kg bw of cadmium (negative con-
trol group)
Group 3: Rats administered cadmium (5 mg/kg bw) and 2.5 mg/kg
bw of prostigmine (positive control group)
Group 4: Rats administered cadmium (5 mg/kg bw) and FA (10 mg/
kg bw)
Group 5: Rats administered cadmium (5 mg/kg bw) and FA (20 mg/
kg bw)
Group 6: Rats administered FA (10 mg/kg bw) only
Group 7: Rats administered FA (20 mg/kg bw) only
Preparation of Tissue Homogenates. The rats were dislocated at the
cervical region and the cerebral tissue (whole brain) was rapidly dis-
sected, placed in phosphate buffer (pH 7.4) on ice, and weighed. This
tissue was subsequently rinsed with the phosphate buffer (pH 7.4) and
later homogenized with the phosphate buffer, pH 7.4 (1:5 w/v), with
about 10 up and down strokes at approximately 1200 rev/min in a
Teflon-glass homogenizer. The homogenate was centrifuged for 10
minutes at 3000 g to yield a pellet that was discarded and the super-
natant was used for all assays.
Methods
Lipid Peroxidation and Thiobarbituric Acid Reactions
The lipid peroxidation assay was carried out according to the modified
method of Ohkawa et al.15 Briefly, 300 mL of the brain homogenate was
added to 300 mL of 8.1% sodium dodecyl sulfate (SDS), 500 mL of
acetic acid/HCl buffer (pH 3.4), and 500 mL of 0.6% thiobarbituric acid
(TBA). This mixture was incubated at 100C for 1 hour, and thiobarbi-
turic acid reactive species (TBARS) produced were measured at 532 nm
using a spectrophotometer. Malondialdehyde (MDA) was used as stan-
dard and TBARS produced was reported as MDA equivalent.
Enzyme Assays
Monoamine Oxidase Activity Assay. The assay for MAO activity was
performed according to the modified method described by Turski
et al.16 In brief, the reaction mixture contained 0.025 M phosphate
buffer of pH 7, 0.0125 M semicarbazide, 10 mM benzylamine (pH
adjusted to 7), and 0.67 mg of tissue. After 30 minutes, 250 mL of
acetic acid was added and boiled for 3 minutes in a boiling water bath
followed by centrifugation. The resultant supernatant (250 mL) was
mixed with equal volume of 0.05% of 2,-DNPH and 1.25 mL of ben-
zene was added after 10 minutes of incubation at room temperature.
After separating the benzene layer, it was mixed with equal volume
of 0.1 N NaOH. The alkaline layer was decanted and heated at
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80C for 10 minutes. The orange-yellow color that developed was
measured at 450 nm in a spectrophotometer. The enzyme’s activity
was expressed in mmol/mg protein.
Cholinesterase (AChE and BChE) Activity Assay. The AChE activity
was investigated according to the modified method of Ellman
et al.17 The AChE activity was determined in a reaction mixture con-
taining 50 mL of brain homogenate, 50 mL of 5,50-dithiobis(2-nitroben-
zoic) acid (DTNB), 1175 mL of 0.1 M phosphate-buffered solution
(pH 8.0). After incubation for 20 minutes at 25C, 25 mL acetylthio-
choline iodide solution was added as the substrate. A total of 25 mL
of butyrylthiocholine iodide was used as a substrate to assay for BChE
activity, while all the other reagents and conditions remained the same.
The AChE and BChE activities were determined as changes in absor-
bance reading at 412 nm for 3 minutes at 25C using a spectrophot-
ometer, and the enzyme’s activities expressed as mmol/mg protein.
Naþ,Kþ-ATPase Activity Assay. The Naþ/Kþ-ATPase activity was
performed according to the modified method described by Wyse
et al.18 The reaction mixture for Naþ,Kþ-ATPase assay contained
120 mMTris–HCl, 0.4 mM EDTA, 200 mM NaCl, 20 mM KCl, and
24 mM MgCl2 (pH 7.4), in a final volume of 200 mL. After 10 minutes
of preincubation at 37C, the reaction was initiated by addition of
50 mL adenosine triphosphate (ATP) to a final concentration of
3.0 mM, and was incubated for 20 minutes. Controls were carried out
under the same conditions with the addition of 50 mL of 1.0 mM oua-
bain. The reaction was terminated by the addition of 50 mL of 10%
(w/v) trichloroacetic acid. The amount of inorganic phosphate (Pi)
released was quantified using a reaction mixture that contained
250 mL of ammonium molybdate (100 mM), 200 mL of reaction mix-
ture from first grid, 500 mL of distilled water, and 50 mL of ascor-
bic acid (8%). Released inorganic phosphate (Pi) was measured at
620 nm in a spectrophotometer. Specific activity of the enzyme
was expressed as nmol of Pi released per minute per mg of protein.
Statistical Analysis
The results of replicate experiments were represented as mean + stan-
dard deviation (SD). Statistical analyses were done using Statistical
Program for Social Science (SPSS) 16.0 (SPSS Inc, Chicago, IL).
One-way analysis of variance was carried out followed by Duncan’s
test for the post hoc treatment. A value of P < .05 was considered to
be statistically significant.
Results
Figure 2 shows that there was an increase in the brain MDA
content of rats administered 5 mg/kg bw of cadmium (negative
control group) when compared to rats administered normal sal-
ine (basal group) and those administered 5 mg/kg bw of cad-
mium and 2.5 mg/kg bw of prostigmine (positive control
group). However, the brain MDA level was significantly
reduced (P < .05) in rats administered cadmium (5 mg/kg
bw) with FA (10 and 20 mg/kg bw) dose dependently. Never-
theless, no significant difference (P > .05) was observed
between the brain MDA content of the basal rat group and nor-
mal rats treated with FA (10 and 20 mg/kg bw) alone.
The results of the effect of cadmium-induced brain damage
on MAO activity is shown in Figure 3. The results showed that
cadmium induced an increase in the MAO activity in rats admi-
nistered cadmium (negative control group), when compared
with the basal group (administered normal saline) and positive
control group (administered cadmium and prostigmine). How-
ever, this was significant reversed (P < .05) in rats administered
cadmium and FA (10 and 20 mg/kg bw) dose dependently,
while there was no significant (P > .05) difference between the
enzyme’s activity in the basal group and rat groups adminis-
tered FA (10 and 20 mg/kg bw) alone.
The effect of cadmium-induced brain damage on cholines-
terase activities in rats showed that there was an increase in the
AChE activity (Figure 4) of rats administered cadmium, when
compared to basal rat group and rats administered cadmium
and prostigmine. However, there was a significant reversal
(P < .05) in the AChE activity of rats administered cadmium
and FA (10 and 20 mg/kg bw). There was no significant (P >
.05) difference between the enzyme’s activity in the basal
group and rat groups treated with FA (10 mg/kg bw) alone.
Similarly, Figure 5 shows that there was an increase in the
BChE activity of rats administered cadmium when compared
to the basal group and rats administered cadmium and prostig-
mine. However this was reversed significantly (P < .05) in rat
groups administered cadmium and FA (10 and 20 mg/kg bw).
There was, in addition, no significant (P > .05) difference
between the enzyme’s activity in the basal rat group, rats admi-
nistered cadmium and 20mg/kg bw of FA, and normal rat
groups treated with FA (10 and 20 mg/kg bw) alone.
We report the effect of cadmium-induced brain damage on
Naþ/Kþ-ATPase activity in rats in Figure 6. This revealed that


























Figure 2. Effect of ferulic acid on lipid peroxidation (MDA content) in
cadmium-induced brain damage in rats.
Key—Group 1: Rats administered normal saline (basal group); Group 2:
negative control rats administered 5 mg/kg body weight (bw) of cad-
mium (Cd); Group 3: positive control rats administered Cd and pros-
tigmine (2.5 mg/kg bw); Group 4: rats administered Cd and 10 mg/kg
bw of ferulic acid; Group 5: rats administered Cd and 20 mg/kg bw
of ferulic acid; Group 6: rats administered 10 mg/kg bw of ferulic acid;
Group 7: rats administered 20 mg/kg bw of ferulic acid.
Values represent mean + standard deviation (n ¼ 5).
*No significant difference at P < .05. **No significant difference at P < .05.
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Figure 3. Effect of ferulic acid on monoamine oxidase (MAO) activity
in cadmium-induced brain damage in rats.
Key—Group 1: Rats administered normal saline (basal group); Group 2:
negative control rats administered 5 mg/kg body weight (bw) of cad-
mium (Cd); Group 3: positive control rats administered Cd and pros-
tigmine (2.5 mg/kg bw); Group 4: rats administered Cd and 10 mg/kg
bw of ferulic acid; Group 5: rats administered Cd and 20 mg/kg bw
of ferulic acid; Group 6: rats administered 10 mg/kg bw of ferulic acid;
Group 7: rats administered 20 mg/kg bw of ferulic acid.
Values represent mean + standard deviation (n ¼ 5).
*No significant difference at P < .05.

























Figure 4. Effect of ferulic acid on acetylcholinesterase (AChE) activity
in cadmium-induced brain damage in rats.
Key—Group 1: Rats administered normal saline (basal group); Group 2:
negative control rats administered 5 mg/kg body weight (bw) of cad-
mium (Cd); Group 3: positive control rats administered Cd and pros-
tigmine (2.5 mg/kg bw); Group 4: rats administered Cd and 10 mg/kg
bw of ferulic acid; Group 5: rats administered Cd and 20 mg/kg bw
of ferulic acid; Group 6: rats administered 10 mg/kg bw of ferulic acid;
Group 7: rats administered 20 mg/kg bw of ferulic acid.
Values represent mean + standard deviation (n ¼ 5).
*No significant difference at P < .05.




























Figure 5. Effect of ferulic acid on butyrylcholinesterase (BChE) activ-
ity in cadmium-induced brain damage in rats.
Key—Group 1: Rats administered normal saline (basal group); Group 2:
negative control rats administered 5 mg/kg body weight (bw) of cad-
mium (Cd); Group 3: positive control rats administered Cd and pros-
tigmine (2.5 mg/kg bw); Group 4: rats administered Cd and 10 mg/kg
bw of ferulic acid; Group 5: rats administered Cd and 20 mg/kg bw
of ferulic acid; Group 6: rats administered 10 mg/kg bw of ferulic acid;
Group 7: rats administered 20 mg/kg bw of ferulic acid.
Values represent mean + standard deviation (n ¼ 5).
*No significant difference at P < .05. **No significant difference at P < .05.


































Figure 6. Effect of ferulic acid on Naþ/Kþ-ATPase activity in
cadmium-induced brain damage in rats.
Key—Group 1: Rats administered normal saline (basal group); Group 2:
negative control rats administered 5 mg/kg body weight (bw) of cad-
mium (Cd); Group 3: positive control rats administered Cd and pros-
tigmine (2.5 mg/kg bw); Group 4: rats administered Cd and 10 mg/kg
bw of ferulic acid; Group 5: rats administered Cd and 20 mg/kg bw
of ferulic acid; Group 6: rats administered 10 mg/kg bw of ferulic acid;
Group 7: rats administered 20 mg/kg bw of ferulic acid.
Values represent mean + standard deviation (n ¼ 5).
*No significant difference at P < .05. **No significant difference at P < .05.
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cadmium induced a significant (P < .05) rise in the activity of
this enzyme in rats administered cadmium (negative control
group) when compared to the basal group rats. However, there
was significant decrease (P < .05) in the enzyme’s activity only
in rats administered cadmium and 20mg/kg bw of FA. More-
over, there was also no significant (P > .05) difference between
the enzyme’s activity in the basal group rats and normal rat
groups administered FA (10 and 20 mg/kg bw) alone.
Discussion
There is growing public and research interest in the use of
phytochemicals derived from dietary sources to combat human
diseases.19 Ferulic acid; a phytochemical commonly found in
fruits and vegetables, has been reported to exhibit a wide range
of therapeutic potentials against various diseases such as can-
cer, diabetes, and cardiovascular and neurodegenerative dis-
eases.4,19 FA is found in abundance in food sources such as
vegetables and fruits and consumption of these food sources
have been estimated to a daily intake of about 150 to 250 mg
of FA.20 It has been established that FA is not degraded by the
acidic nature of the stomach and is well absorbed into the blood
plasma in its active form.5,6
The increased MDA content in cadmium-administered rats
suggests enhanced lipid peroxidation induced by cadmium
administration. Oxidative attack on polyunsaturated fatty acids
of biological membrane may compromise their integrity and
functions.21 The damage caused by lipid peroxidation is highly
detrimental to the functioning of cells and its survival.22 How-
ever, this agrees with previous reports that cadmium induced its
cellular toxicity by indirectly stimulating reactive oxygen pro-
duction and thus stimulating oxidative stress.3 However, there
was significant reduction in the MDA content of rats treated with
cadmium and FA in a dose-dependent manner (10 and 20 mg/kg
bw). This could be as a result of the antioxidant property of FA as
previously reported; Srinivasan et al19 reported the antioxidant
property of FA and stated that it can effectively scavenge super-
oxide anion radicals and inhibit lipid peroxidation, while Trom-
bino et al14 also reported that FA inhibited peroxyl radical–
induced lipid peroxidation in reconstituted rat brain microsomes.
Excessive MAO activity has been linked to increased gener-
ation of free radicals in the brain and, consequently, neuronal
damage.23 Therefore, possible inhibition of MAO activity may
be a therapeutic target toward the management of Alzheimer’s
disease and other neurodegenerative conditions.24 The increased
MAO activity in cadmium-administered rats (negative control
group) may therefore be another indicator of impaired neuronal
functions leading to brain damage. However, the significant and
dose-dependent reduction in the MAO activity in rats adminis-
tered cadmium and FA (10 and 20 mg/kg bw) may indicate that
FA was able to inhibit the formation of hydrogen peroxide and
ammonia, which are potentially harmful products of amine
degradation, thereby acting as MAO inhibitors and exerting its
neuroprotective potentials.25
Cholinesterases (AChE and BChE) are enzymes relevant to
cognitive functions and memory, and they have been shown to
be therapeutic targets in the management of several neurode-
generative diseases, especially Alzheimer’s disease.26 There-
fore, the use AChE and BChE inhibitors to reduce the
hydrolysis of acetylcholine may be a good approach toward the
treatment and management of neurodegeneration.24 Normally,
in the healthy brain, AChE is predominant. However, on neu-
ronal damage BChE activity rises while AChE activity remains
unchanged or diminishes.27 The observed increases in both
AChE and BChE activities in cadmium-administered rats are
potential indicators of neuronal damage induced by cadmium.
Interestingly, the administration of cadmium with FA (10 and
20 mg/kg bw) led to a significant reversal in the enzymes’
activities and could further corroborate the neuroprotective
potentials of FA. It is noteworthy that administration of cad-
mium with 10kg/mg bw reduced the BChE activity to a level not
significantly different from that produced when cadmium was
administered with the standard cholinesterase inhibitor—pros-
tigmine. Similarly, rats administered cadmium with 20 mg/kg
bw of FA reduced the rise in BChE activity induced by cadmium
to the levels not significantly different from those observed in
basal rats or rats administered FA alone.
Furthermore, we observed that brain damage induced by
cadmium in this study led to the increase in the activity of
Naþ/Kþ-ATPase. This enzyme is essential for proper neuronal
function; it helps in maintaining action potential across mem-
branes and acts as a secondary active transporter.12 Therefore,
impairment in its function by overstimulation can lead to neu-
ronal damage. However, administration of FA with 20 mg/kg
bw gave a significant reversal in the increase of Naþ/Kþ-
ATPase activity induced by cadmium.
Conclusion
This study has been able to show that cadmium at a dose of 5
mg/kg body weight was able to induce brain damage in rats as
shown by elevated MDA contents as well as increased activi-
ties of Naþ/Kþ-ATPase, cholinergic, and monoaminergic
enzymes essential for proper brain functioning. However, rats
administered cadmium with FA (10 and 20 mg/kg bw) showed
a significant reduction in both MDA contents and enzymes’
(AChE, BChE, MAO, and Naþ/Kþ-ATPase) activities. This
could therefore further substantiate the possible neuroprotec-
tive potentials of FA, especially in the management of heavy
metal toxicity; nevertheless, further experimental studies and
clinical trials are recommended.
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